• SSY Group won China NMPA production and registration clearance for Cimetidine Injection, treated as passing the consistency evaluation.
• NMPA also cleared Acetylcysteine Solution for Inhalation, treated as passing the consistency evaluation, expanding the group’s nebulized respiratory portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261364), on July 30, 2026, and is solely responsible for the information contained therein.